Basic Information
NovoSeven® powder and solvent for solution for injection 2mg
INJECTION, POWDER, FOR SOLUTION
Regulatory Information
SIN13934P
March 17, 2011
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
May 30, 2025
XB02BD08
Company Information
NOVO NORDISK PHARMA (SINGAPORE) PTE LTD
NOVO NORDISK PHARMA (SINGAPORE) PTE LTD
Active Ingredients
Strength: 2mg
Detailed Information
Contraindications
**Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in List of excipients – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_, or to mouse, hamster or bovine protein.
Indication Information
**Therapeutic indications** NovoSeven® is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups: - in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 Bethesda Units (BU) - in patients with congenital haemophilia who are expected to have a high anamnestic response to factor VIII or factor IX administration - in patients with acquired haemophilia